Chronic Gout
Gout is a metabolic disease caused by monosodium urate crystal deposition in joints and tissues due to persistent hyperuricemia. Chronic gout features frequent flares, tophi, joint damage, and kidney involvement. Treat-to-target urate-lowering therapy can prevent flares and resolve tophi.
Risk Factors
- Genetics affecting urate transporters (SLC2A9, ABCG2)
- Purine-rich diets, high fructose corn syrup, alcohol (beer, spirits)
- Obesity, metabolic syndrome, insulin resistance
- Chronic kidney disease, diuretics, cyclosporine, tacrolimus
- Male sex, postmenopausal women
Symptoms & Phases
- Acute flares: sudden, severe monoarthritis (often first MTP joint), redness, warmth
- Intercritical gout: asymptomatic periods between flares
- Chronic tophaceous gout: tophi in joints, bursae, tendons, ears; joint deformities
- Uric acid nephrolithiasis or nephropathy
Diagnosis
- Joint aspiration showing negatively birefringent needle-shaped crystals (gold standard)
- Serum uric acid > 6.8 mg/dL (may be normal during flares)
- Imaging: ultrasound double-contour sign, dual-energy CT for crystal deposits
- Assess renal function, medications, comorbidities
Treatment Strategy
Acute Flare Management
- NSAIDs, colchicine (low-dose regimen), or glucocorticoids (oral, intra-articular)
- IL-1 inhibitors (anakinra) for refractory flares
- Treat quickly; continue urate-lowering therapy (ULT) during flares
Urate-Lowering Therapy (Treat-to-Target)
- Allopurinol (first-line): start 100 mg/day, titrate up; higher doses safe with monitoring
- Febuxostat for allopurinol intolerance; monitor CV risk
- Uricosurics (probenecid, lesinurad) if underexcretion; require good renal function
- Pegloticase for severe refractory tophaceous gout
- Target serum urate < 6 mg/dL (or < 5 mg/dL for tophaceous disease)
- Use prophylaxis (colchicine, NSAID) for 3–6 months when initiating ULT to prevent flare
Lifestyle & Comorbidity Management
- Limit alcohol (especially beer), reduce sugary beverages, portion control high-purine foods
- Weight loss, exercise, blood pressure/glucose/lipids control
- Stay hydrated; monitor for kidney stones
Living with Chronic Gout
- Track uric acid, medications, flares, triggers (diet, alcohol, dehydration)
- Ensure adherence—consistent ULT prevents future attacks
- Protect joints with supportive footwear, physical therapy
- Address mental health—chronic pain and stigma are common
Complications
- Chronic joint damage, deformities, disability
- Uric acid kidney stones or chronic kidney disease
- Cardiovascular disease associations
- Subcutaneous tophi infections/ulcerations
Research & Future Directions
Focus on novel uricosurics, biologics targeting urate transporters, and personalized dosing algorithms.
Experimental & Emerging Treatments
- URAT1/GLUT9 Dual Inhibitors: Aim to increase renal urate excretion with fewer drug interactions.
- Pegloticase + Immunomodulators: Co-therapy with methotrexate reduces anti-drug antibodies and infusion reactions.
- Gene Therapy: Research explores correcting purine metabolism defects or enhancing uricase expression.
- Digital Adherence Tools: Smart pill bottles/patches monitor ULT adherence to reduce flares.
Track Gout with Diagnoza.care
Keep Uric Acid in Check – Log uric acid levels, flares, tophi size, medications, diet, alcohol, hydration, and comorbid treatments; schedule rheumatology visits; capture side effects; and let the AI companion alert you when urate targets aren’t met.
Medical Disclaimer: Informational only. Work with your rheumatologist or primary care provider to personalize urate-lowering therapy, monitor comorbidities, and manage flares safely.
Sources: American College of Rheumatology, European League Against Rheumatism, National Kidney Foundation